SHINE SPECT

SHINE SPECT is a leading radiopharmaceutical company and a subsidiary of SHINE Technologies, established through the acquisition of Lantheus Holdings' SPECT business in 2026. The company specializes in the production and distribution of critical diagnostic radiopharmaceuticals, including the TechneLite technetium-99m generator and imaging agents like Cardiolite and Neurolite. Operating out of a long-standing manufacturing facility in North Billerica, Massachusetts, SHINE SPECT provides a vertically integrated supply chain for medical isotopes. By leveraging the parent company's proprietary fusion-based isotope production technology, SHINE SPECT aims to modernize the nuclear medicine market and ensure a reliable, domestic supply of isotopes for millions of patients. The company's portfolio supports a wide range of diagnostic procedures for cardiac, pulmonary, and oncological conditions.